Clinical outcomes posttransplant, per arm
| Outcome . | AC estimate (95% CI) . | TMS estimate (95% CI) . | P value . |
|---|---|---|---|
| Grade 3-4 aGVHD∗ | |||
| 100 d | 0.32 (0.19-0.46) | 0.31 (0.17-0.46) | .75 |
| 180 d | 0.39 (0.24-0.53) | 0.41 (0.25-0.56) | |
| Grade 3-4 aGVHD∗ | |||
| 100 d | 0.18 (0.08-0.31) | 0.10 (0.03-0.22) | .52 |
| 180 d | 0.23 (0.12-0.36) | 0.16 (0.06-0.29) | |
| cGVHD of any grade∗ | |||
| 2 y | 0.25 (0.13-0.39) | 0.54 (0.37-0.68) | .0029 |
| 5 y | 0.25 (0.13-0.39) | 0.59 (0.41-0.79) | |
| Moderate-to-severe cGVHD∗ | |||
| 2 y | 0.11 (0.04-0.23) | 0.51 (0.34-0.66) | <.0001 |
| 5 y | 0.11 (0.04-0.23) | 0.54 (0.37-0.68) | |
| Severe cGVHD∗ | |||
| 2 y | 0.05 (0.008-0.14) | 0.26 (0.13-0.40) | .0002 |
| 5 y | 0.05 (0.008-0.14) | 0.29 (0.23-0.54) | |
| Moderate-to-severe CFS | |||
| 2 y | 0.39 (0.25-0.54) | 0.18 (0.08-0.31) | .06 |
| 5 y | 0.27 (0.15-0.49) | 0.08 (0.02-0.19) | |
| GRFS | |||
| 2 y | 0.18 (0.09-0.31) | 0.18 (0.08-0.31) | .71 |
| 5 y | 0.14 (0.06-0.25) | 0.08 (0.02-0.19) | |
| OS | |||
| 2 y | 0.48 (0.33-0.62) | 0.72 (0.55-0.83) | .30 |
| 5 y | 0.36 (0.23-0.50) | 0.46 (0.30-0.61) | |
| Progression-free survival | |||
| 2 y | 0.25 (0.14-0.38) | 0.59 (0.42-0.73) | .014 |
| 5 y | 0.18 (0.09-0.31) | 0.41 (0.26-0.56) | |
| Nonrelapse mortality† | |||
| 2 y | 0.27 (0.15-0.41) | 0.21 (0.10-0.35) | .33 |
| 5 y | 0.30 (0.17-0.44) | 0.39 (0.23-0.54) | |
| Relapse‡ | |||
| 2 y | 0.48 (0.32-0.62) | 0.21 (0.10-0.35) | .0027 |
| 5 y | 0.52 (0.36-0.66) | 0.21 (0.10-0.35) |
| Outcome . | AC estimate (95% CI) . | TMS estimate (95% CI) . | P value . |
|---|---|---|---|
| Grade 3-4 aGVHD∗ | |||
| 100 d | 0.32 (0.19-0.46) | 0.31 (0.17-0.46) | .75 |
| 180 d | 0.39 (0.24-0.53) | 0.41 (0.25-0.56) | |
| Grade 3-4 aGVHD∗ | |||
| 100 d | 0.18 (0.08-0.31) | 0.10 (0.03-0.22) | .52 |
| 180 d | 0.23 (0.12-0.36) | 0.16 (0.06-0.29) | |
| cGVHD of any grade∗ | |||
| 2 y | 0.25 (0.13-0.39) | 0.54 (0.37-0.68) | .0029 |
| 5 y | 0.25 (0.13-0.39) | 0.59 (0.41-0.79) | |
| Moderate-to-severe cGVHD∗ | |||
| 2 y | 0.11 (0.04-0.23) | 0.51 (0.34-0.66) | <.0001 |
| 5 y | 0.11 (0.04-0.23) | 0.54 (0.37-0.68) | |
| Severe cGVHD∗ | |||
| 2 y | 0.05 (0.008-0.14) | 0.26 (0.13-0.40) | .0002 |
| 5 y | 0.05 (0.008-0.14) | 0.29 (0.23-0.54) | |
| Moderate-to-severe CFS | |||
| 2 y | 0.39 (0.25-0.54) | 0.18 (0.08-0.31) | .06 |
| 5 y | 0.27 (0.15-0.49) | 0.08 (0.02-0.19) | |
| GRFS | |||
| 2 y | 0.18 (0.09-0.31) | 0.18 (0.08-0.31) | .71 |
| 5 y | 0.14 (0.06-0.25) | 0.08 (0.02-0.19) | |
| OS | |||
| 2 y | 0.48 (0.33-0.62) | 0.72 (0.55-0.83) | .30 |
| 5 y | 0.36 (0.23-0.50) | 0.46 (0.30-0.61) | |
| Progression-free survival | |||
| 2 y | 0.25 (0.14-0.38) | 0.59 (0.42-0.73) | .014 |
| 5 y | 0.18 (0.09-0.31) | 0.41 (0.26-0.56) | |
| Nonrelapse mortality† | |||
| 2 y | 0.27 (0.15-0.41) | 0.21 (0.10-0.35) | .33 |
| 5 y | 0.30 (0.17-0.44) | 0.39 (0.23-0.54) | |
| Relapse‡ | |||
| 2 y | 0.48 (0.32-0.62) | 0.21 (0.10-0.35) | .0027 |
| 5 y | 0.52 (0.36-0.66) | 0.21 (0.10-0.35) |
Time to event analyses estimating cumulative incidence with competing risks.
Boldface is if the p-value is significant.
Cumulative incidence of clinical outcome competing with death, relapse, graft failure, cGVHD without prior aGVHD (for aGVHD only).
Cumulative incidence competing with relapse.
Cumulative incidence competing with death and graft failure.